English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Aim: This study investigated the pharmacokinetics, excretion and metabolism of [ 14 C]-GCC-4401C, a factor Xa inhibitor, using a microtracer approach. Results/methodology: Total [ 14 C] in excreta and plasma, and radiochromatographic profiles were determined using accelerator MS and liquid scintillation counting. LC/MS was used to assess pharmacokinetics and metabolism. The average plasma exposure for [ 14 C] was higher than for GCC-4401C, indicating that metabolites with a longer half-life than GCC-4401C were formed. Mean total recovery of [ 14 C] in urine and feces was 87.3%. GCC-4401C was the primary contributor (58%) to total radioactivity in plasma. A total of 12 metabolites were identified; M11 and M12 were the major circulating metabolites. The major metabolic routes of GCC-4401C in humans were oxidation and dehydrogenation. Discussion/conclusion: The study successfully assessed the elimination and metabolism of GCC-4401C.

Metabolism and excretion of GCC-4401C, a factor Xa inhibitor, in humans